Alkermes (ALKS)

• Market cap: $5.09B
• 1 day: 0.87%
• 5 days: 8.48%
• 1 month: 7.41%
• 3 months: 17.13%
• 6 months: 30.22%
• Year to date: 9.92%
• 1 year: 19.12%
• 5 years: 50.17%
• 10 years: -46.22%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.

Employees: 2,100

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

200% more funds holding in top 10

Funds holding in top 10: 1 [Q2] → 3 (+2) [Q3]

109% more call options, than puts

Call options by funds: $4.6M | Put options by funds: $2.2M

33% more first-time investments, than exits

New positions opened: 57 | Existing positions closed: 43

13% more capital invested

Capital invested by funds: $4.37B [Q2] → $4.94B (+$573M) [Q3]

4% more funds holding

Funds holding: 320 [Q2] → 334 (+14) [Q3]

1% more repeat investments, than reductions

Existing positions increased: 118 | Existing positions reduced: 117

2.82% less ownership

Funds ownership: 107.22% [Q2] → 104.4% (-2.82%) [Q3]

Research analyst outlook

10 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $26 17% downside
• Avg. target: $38 21% upside
• High target: $48 53% upside

10 analyst ratings

• positive: 7 70%
• neutral: 3 30%
• negative: 0 0%

Mizuho Uy Ear 56% 1-year accuracy 5 / 9 met price target	27% upside $40	Outperform Maintained	13 Nov 2024
Stifel Paul Matteis 20% 1-year accuracy 3 / 15 met price target	14% upside $36	Buy Upgraded	5 Nov 2024
Goldman Sachs Chris Shibutani 64% 1-year accuracy 7 / 11 met price target	5% downside $30	Buy Maintained	25 Oct 2024
Cantor Fitzgerald Charles Duncan 57% 1-year accuracy 32 / 56 met price target	37% upside $43	Overweight Maintained	25 Oct 2024
JP Morgan Jessica Fye 63% 1-year accuracy 17 / 27 met price target	17% downside $26	Neutral Maintained	25 Oct 2024